CRTH2 and D-Type Prostanoid Receptor Antagonists as Novel Therapeutic Agents for Inflammatory Diseases
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Accumulation of type 2 T helper (Th2) lymphocytes and eosinophils is a hallmark of bronchial asthma and other allergic diseases, and it is believed that these cells play a crucial pathogenic role in allergic inflammation. Thus, Th2 cells and eosinophils are currently considered a major therapeutic target in allergic diseases and asthma. However, drugs that selectively target the accumulation and activation of Th2 cells and eosinophils in tissues are unavailable so far. Prostaglandin (PG)D 2 is a key mediator in various inflammatory diseases including allergy and asthma. It is generated by activated mast cells after allergen exposure and subsequently orchestrates the recruitment of inflammatory cells to the tissue. PGD 2 induces the chemotaxis of Th2 cells, basophils and eosinophils, stimulates cytokine release from these cells and prolongs their survival, and might hence indirectly promote IgE production. PGD 2 mediates its biologic functions via 2 distinct G protein-coupled receptors, D-type prostanoid receptor (DP), and the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). DP and CRTH2 receptors are currently being considered as highly promising therapeutic targets for combating allergic diseases and asthma. Here, we revisit the roles of PGD 2 receptors in the regulation of eosinophil and Th2 cell function and the efforts towards developing candidate compounds for clinical evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iwasaki, M., Nagata, K., Takano, S., Takahashi, K., Ishii, N., & Ikezawa, Z. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01862.x · Cited by 86
PGD2 metabolism in plasma: Kinetics and relationship with bioactivity on DP1 and CRTH2 receptors
Schuligoi, R., Schmidt, R., Geisslinger, G., Kollroser, M., Peskar, B. A., & Heinemann, A. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.023 · Cited by 73
Self-citationKobayashi, Y., Ueki, S., Mahemuti, G., Chiba, T., Oyamada, H., Saito, N., Kanda, A., Kayaba, H., & Chihara, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5744 · Cited by 57
Cited by
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Targeting eosinophils in allergy, inflammation and beyond
Fulkerson, P. C., & Rothenberg, M. E. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3838 · Cited by 482
Pathophysiology of allergic inflammation
Barnes, P. J. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01020.x · Cited by 361
“CRTH2 ⁄ DP2 antagonists are now in development as oral antiallergic therapies (74, 75).”
BackgroundEosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation
Luna-Gomes, T., Magalhães, K. G., Mesquita-Santos, F. P., Bakker-Abreu, I., Samico, R. F., Molinaro, R., Calheiros, A. S., Diaz, B. L., Bozza, P. T., Weller, P. F., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101806 · Cited by 87
Marone, G., Galdiero, M. R., Pecoraro, A., Pucino, V., Criscuolo, G., Triassi, M., & Varricchi, G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1555237 · Cited by 62
“Engagement of DP2 receptor results in the inhibitory G-protein (Gi) with subsequent increased intracellular calcium level and reduced adenylyl cyclase activity and intracellular cAMP concentration [40,57].”
Background
Metadata
- Authors
- Schuligoi, R., Sturm, E., Luschnig, P., Konya, V., Philipose, S., Sedej, M., Waldhoer, M., Peskar, B. A., & Heinemann, A.
- Venue
- Pharmacology
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 85
- Issue
- 6
- Pages
- 372-382
- ISSN
- 0031-7012 (ISSN-L)
- 1423-0313
- OpenAlex
- W1985242752
- Cited by
- 110
- References
- 3
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.